Enhanced AKT phosphorylation of circulating B cells in patients with activated PI3Kδ syndrome

Takaki Asano, Satoshi Okada, Miyuki Tsumura, Tzu Wen Yeh, Kanako Mitsui-Sekinaka, Yuki Tsujita, Youjiro Ichinose, Akira Shimada, Kunio Hashimoto, Taizo Wada, Kohsuke Imai, Osamu Ohara, Tomohiro Morio, Shigeaki Nonoyama, Masao Kobayashi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Activated PI3Kδ syndrome (APDS) is a primary immunodeficiency characterized by recurrent respiratory tract infections, lymphoproliferation, and defective IgG production. Heterozygous mutations in PIK3CD, PIK3R1, or PTEN, which are related to the hyperactive phosphoinositide 3-kinase (PI3K) signaling, were recently presented to cause APDS1 or APDS2 (APDSs), or APDS-like (APDS-L) disorder. In this study, we examined the AKT phosphorylation of peripheral blood lymphocytes and monocytes in patients with APDSs and APDS-L by using flow cytometry. CD19+ B cells of peripheral blood in APDS2 patients showed the enhanced phosphorylation of AKT at Ser473 (pAKT) without any specific stimulation. The enhanced pAKT in CD19+ B cells was normalized by the addition of a p110δ inhibitor. In contrast, CD3+ T cells and CD14+ monocytes did not show the enhanced pAKT in the absence of stimulation. These findings were similarly observed in patients with APDS1 and APDS-L. Among CD19+ B cells, enhanced pAKT was prominently detected in CD10+ immature B cells compared with CD10- mature B cells. Enhanced pAKT was not observed in B cells of healthy controls, patients with common variable immunodeficiency, and hyper IgM syndrome due to CD40L deficiency. These results suggest that the enhanced pAKT in circulating B cells may be useful for the discrimination of APDS1, APDS2, and APDS-L from other antibody deficiencies.

Original languageEnglish
Article number568
JournalFrontiers in Immunology
Volume9
Issue numberAPR
DOIs
Publication statusPublished - Apr 5 2018

Fingerprint

1-Phosphatidylinositol 4-Kinase
B-Lymphocytes
Phosphorylation
Monocytes
Hyper-IgM Immunodeficiency Syndrome
Common Variable Immunodeficiency
CD40 Ligand
B-Lymphoid Precursor Cells
Respiratory Tract Infections
Flow Cytometry
Immunoglobulin G
Lymphocytes
T-Lymphocytes
Mutation
Antibodies

Keywords

  • Activated PI3 kinase delta syndrome
  • AKT phosphorylation
  • Catalytic subunit p110δ of phosphatidylinositol 3-kinase
  • Flow cytometry
  • Immunodeficiency
  • Regulatory subunit p85a of phosphatidylinositol 3-kinase

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Asano, T., Okada, S., Tsumura, M., Yeh, T. W., Mitsui-Sekinaka, K., Tsujita, Y., ... Kobayashi, M. (2018). Enhanced AKT phosphorylation of circulating B cells in patients with activated PI3Kδ syndrome. Frontiers in Immunology, 9(APR), [568]. https://doi.org/10.3389/fimmu.2018.00568

Enhanced AKT phosphorylation of circulating B cells in patients with activated PI3Kδ syndrome. / Asano, Takaki; Okada, Satoshi; Tsumura, Miyuki; Yeh, Tzu Wen; Mitsui-Sekinaka, Kanako; Tsujita, Yuki; Ichinose, Youjiro; Shimada, Akira; Hashimoto, Kunio; Wada, Taizo; Imai, Kohsuke; Ohara, Osamu; Morio, Tomohiro; Nonoyama, Shigeaki; Kobayashi, Masao.

In: Frontiers in Immunology, Vol. 9, No. APR, 568, 05.04.2018.

Research output: Contribution to journalArticle

Asano, T, Okada, S, Tsumura, M, Yeh, TW, Mitsui-Sekinaka, K, Tsujita, Y, Ichinose, Y, Shimada, A, Hashimoto, K, Wada, T, Imai, K, Ohara, O, Morio, T, Nonoyama, S & Kobayashi, M 2018, 'Enhanced AKT phosphorylation of circulating B cells in patients with activated PI3Kδ syndrome', Frontiers in Immunology, vol. 9, no. APR, 568. https://doi.org/10.3389/fimmu.2018.00568
Asano, Takaki ; Okada, Satoshi ; Tsumura, Miyuki ; Yeh, Tzu Wen ; Mitsui-Sekinaka, Kanako ; Tsujita, Yuki ; Ichinose, Youjiro ; Shimada, Akira ; Hashimoto, Kunio ; Wada, Taizo ; Imai, Kohsuke ; Ohara, Osamu ; Morio, Tomohiro ; Nonoyama, Shigeaki ; Kobayashi, Masao. / Enhanced AKT phosphorylation of circulating B cells in patients with activated PI3Kδ syndrome. In: Frontiers in Immunology. 2018 ; Vol. 9, No. APR.
@article{da604e0d988f4b8d9d9c5baf5c9c945e,
title = "Enhanced AKT phosphorylation of circulating B cells in patients with activated PI3Kδ syndrome",
abstract = "Activated PI3Kδ syndrome (APDS) is a primary immunodeficiency characterized by recurrent respiratory tract infections, lymphoproliferation, and defective IgG production. Heterozygous mutations in PIK3CD, PIK3R1, or PTEN, which are related to the hyperactive phosphoinositide 3-kinase (PI3K) signaling, were recently presented to cause APDS1 or APDS2 (APDSs), or APDS-like (APDS-L) disorder. In this study, we examined the AKT phosphorylation of peripheral blood lymphocytes and monocytes in patients with APDSs and APDS-L by using flow cytometry. CD19+ B cells of peripheral blood in APDS2 patients showed the enhanced phosphorylation of AKT at Ser473 (pAKT) without any specific stimulation. The enhanced pAKT in CD19+ B cells was normalized by the addition of a p110δ inhibitor. In contrast, CD3+ T cells and CD14+ monocytes did not show the enhanced pAKT in the absence of stimulation. These findings were similarly observed in patients with APDS1 and APDS-L. Among CD19+ B cells, enhanced pAKT was prominently detected in CD10+ immature B cells compared with CD10- mature B cells. Enhanced pAKT was not observed in B cells of healthy controls, patients with common variable immunodeficiency, and hyper IgM syndrome due to CD40L deficiency. These results suggest that the enhanced pAKT in circulating B cells may be useful for the discrimination of APDS1, APDS2, and APDS-L from other antibody deficiencies.",
keywords = "Activated PI3 kinase delta syndrome, AKT phosphorylation, Catalytic subunit p110δ of phosphatidylinositol 3-kinase, Flow cytometry, Immunodeficiency, Regulatory subunit p85a of phosphatidylinositol 3-kinase",
author = "Takaki Asano and Satoshi Okada and Miyuki Tsumura and Yeh, {Tzu Wen} and Kanako Mitsui-Sekinaka and Yuki Tsujita and Youjiro Ichinose and Akira Shimada and Kunio Hashimoto and Taizo Wada and Kohsuke Imai and Osamu Ohara and Tomohiro Morio and Shigeaki Nonoyama and Masao Kobayashi",
year = "2018",
month = "4",
day = "5",
doi = "10.3389/fimmu.2018.00568",
language = "English",
volume = "9",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S. A.",
number = "APR",

}

TY - JOUR

T1 - Enhanced AKT phosphorylation of circulating B cells in patients with activated PI3Kδ syndrome

AU - Asano, Takaki

AU - Okada, Satoshi

AU - Tsumura, Miyuki

AU - Yeh, Tzu Wen

AU - Mitsui-Sekinaka, Kanako

AU - Tsujita, Yuki

AU - Ichinose, Youjiro

AU - Shimada, Akira

AU - Hashimoto, Kunio

AU - Wada, Taizo

AU - Imai, Kohsuke

AU - Ohara, Osamu

AU - Morio, Tomohiro

AU - Nonoyama, Shigeaki

AU - Kobayashi, Masao

PY - 2018/4/5

Y1 - 2018/4/5

N2 - Activated PI3Kδ syndrome (APDS) is a primary immunodeficiency characterized by recurrent respiratory tract infections, lymphoproliferation, and defective IgG production. Heterozygous mutations in PIK3CD, PIK3R1, or PTEN, which are related to the hyperactive phosphoinositide 3-kinase (PI3K) signaling, were recently presented to cause APDS1 or APDS2 (APDSs), or APDS-like (APDS-L) disorder. In this study, we examined the AKT phosphorylation of peripheral blood lymphocytes and monocytes in patients with APDSs and APDS-L by using flow cytometry. CD19+ B cells of peripheral blood in APDS2 patients showed the enhanced phosphorylation of AKT at Ser473 (pAKT) without any specific stimulation. The enhanced pAKT in CD19+ B cells was normalized by the addition of a p110δ inhibitor. In contrast, CD3+ T cells and CD14+ monocytes did not show the enhanced pAKT in the absence of stimulation. These findings were similarly observed in patients with APDS1 and APDS-L. Among CD19+ B cells, enhanced pAKT was prominently detected in CD10+ immature B cells compared with CD10- mature B cells. Enhanced pAKT was not observed in B cells of healthy controls, patients with common variable immunodeficiency, and hyper IgM syndrome due to CD40L deficiency. These results suggest that the enhanced pAKT in circulating B cells may be useful for the discrimination of APDS1, APDS2, and APDS-L from other antibody deficiencies.

AB - Activated PI3Kδ syndrome (APDS) is a primary immunodeficiency characterized by recurrent respiratory tract infections, lymphoproliferation, and defective IgG production. Heterozygous mutations in PIK3CD, PIK3R1, or PTEN, which are related to the hyperactive phosphoinositide 3-kinase (PI3K) signaling, were recently presented to cause APDS1 or APDS2 (APDSs), or APDS-like (APDS-L) disorder. In this study, we examined the AKT phosphorylation of peripheral blood lymphocytes and monocytes in patients with APDSs and APDS-L by using flow cytometry. CD19+ B cells of peripheral blood in APDS2 patients showed the enhanced phosphorylation of AKT at Ser473 (pAKT) without any specific stimulation. The enhanced pAKT in CD19+ B cells was normalized by the addition of a p110δ inhibitor. In contrast, CD3+ T cells and CD14+ monocytes did not show the enhanced pAKT in the absence of stimulation. These findings were similarly observed in patients with APDS1 and APDS-L. Among CD19+ B cells, enhanced pAKT was prominently detected in CD10+ immature B cells compared with CD10- mature B cells. Enhanced pAKT was not observed in B cells of healthy controls, patients with common variable immunodeficiency, and hyper IgM syndrome due to CD40L deficiency. These results suggest that the enhanced pAKT in circulating B cells may be useful for the discrimination of APDS1, APDS2, and APDS-L from other antibody deficiencies.

KW - Activated PI3 kinase delta syndrome

KW - AKT phosphorylation

KW - Catalytic subunit p110δ of phosphatidylinositol 3-kinase

KW - Flow cytometry

KW - Immunodeficiency

KW - Regulatory subunit p85a of phosphatidylinositol 3-kinase

UR - http://www.scopus.com/inward/record.url?scp=85045038400&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045038400&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2018.00568

DO - 10.3389/fimmu.2018.00568

M3 - Article

AN - SCOPUS:85045038400

VL - 9

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - APR

M1 - 568

ER -